Search

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.

Read more

EHA Mentorship Program eligibility

Before applying for the EHA Mentorship Program, please consider the eligibility criteria on this page. You should also read our policy on life events.

Read more

Highlights of Past EHA (HOPE) Asia 2019

The 1st edition of the Highlights of Past EHA (HOPE) Asia 2019 took place in Kolkata, India. The meeting was organized in partnership with regional and national societies in Asia.

Read more

Speaker Guidelines

On this page you can find the detailed instructions for your abstract and presentation, as referred to in the Confirmation email.

Read more

1st joint EHA – Balkan Hematology Day, a meeting of true regional commitment

1st joint EHA – Balkan Hematology Day

Friday, October 11, 2019 | Pravets, Bulgaria

Meeting Chairs:

Prof Gert Ossenkoppele, Chair EHA Education Committee
Prof Gianluca Gaidano, Chair EHA Global Outreach Program Unit
Prof Margarita Guenova, Representative Balkan Societies

On Friday, October 11th the European Hematology Association (EHA)…

Read more

Transfusion

The aim of this SWG is to strengthen and invigorate European research in transfusion, to foster new networks and collaborations, with the ultimate goal of optomisingtransfusion practice in Europe based on scientific evidence.

Read more